Navigation Links
Oregon researchers say supplement cuts muscle loss in knee replacements
Date:10/25/2013

reatment group, whereas in the placebo group those times on all of the functional measures were much longer. That suggests that this is a means at which we can accelerate functional recovery."

Faster recovery is a big plus for patients, because most of them have been dealing with pain for a long time, said Dr. Brian A. Jewett, a surgeon at the Slocum Center for Orthopedics & Sports Medicine.

"Walking and being physically active are difficult for them pre-operatively and post-operatively, but for different reasons," he said. "Surgery removes the pre-operative pain and disability, and physical therapy helps restore range of motion and strength post-operatively. EAA appear to facilitate this process, presumably by reducing muscle loss. In the end, if I can get my patients able to go up and down stairs and get up from a chair sooner then this is much better for their overall health, and we saw this occur 6 weeks after surgery in the EAA group. This also suggests a durability-of-treatment effect because EAA treatment was stopped two weeks after surgery and functional mobility measures were recorded four weeks later, or six weeks after TKA. This is clinically very important to me and my patients."

Six weeks after surgery, patients in the control group took 32 percent more time to rise from a chair, walk three meters (about 10 feet), turn around and sit back down, compared to before surgery. Patients receiving essential amino acids took about the same amount of time as before surgery. Control patients took even longer to maneuver stairs after surgery. Again, times remained the same for the EEA group pre- and post-operatively.

"As we've measured it," Dreyer said, "many who have this surgery experience significant and rapid loss of muscle mass despite the fact that their activity level does not change dramatically relative to pre-surgery, which is low to begin with because of their knee pain."

The essential amino acid supplement c
'/>"/>

Contact: Jim Barlow
jebarlow@uoregon.edu
541-346-3481
University of Oregon
Source:Eurekalert  

Page: 1 2 3 4

Related biology news :

1. Oregon Biodiversity Information Center wins 2013 Natureserve Network Collaboration Award
2. Ken Bierly of the Oregon Watershed Enhancement Board to receive ESA Regional Policy Award
3. BUSM researchers identify molecule that could aid lung cancer detection, treatment
4. Researchers identify gene variant that raises risk for colorectal cancer from eating processed meat
5. Researchers show how plants tell the time
6. Berkeley Lab researchers get a detailed look at a DNA repair protein in action
7. Researchers capture images of open channel that moves proteins across cell membranes
8. UAlberta medical researchers discover potential new treatment for colitis
9. Older siblings cells can be passed from female dogs to their puppies in the womb, MU researchers find
10. Nitrogen fertilizer remains in soils and leaks towards groundwater for decades, researchers find
11. Researchers discover innate virus-killing power in mammals
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Oregon researchers say supplement cuts muscle loss in knee replacements
(Date:6/26/2015)... SPRINGVILLE, Utah , June 26, 2015 ATL ... assemblies and devices with specialties in single use solutions, headquartered ... acquisition of MedConx, Inc. (a California ... , and San Jose, Costa Rica ). ... Costa Rica with ATL Technology,s existing ...
(Date:6/24/2015)... , June 24, 2015 The biologics ... The major drivers for the market include growth of ... of new drug launches. Over the years, the number ... Between 2001 and 2010, the FDA approved 225 drug ... to WIPO, Europe accounted for ...
(Date:6/24/2015)... , June 24, 2015 Biometry authentication ... emerging biometric password solution one face in. ... one face in, entering the expanding ... and affordable multifactor-authentication biometric answer to the password ... provided in partnership with KeyLemon, one face in ...
Breaking Biology News(10 mins):ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4KeyLemon Announces Partnership With Biometric Password Solution onefacein 2
... MD The Federation of American Societies for ... for the Science Research Conference (SRC): Neural Mechanisms ... Research Conference, Neural Mechanisms in Cardiovascular Regulation, is ... focus on neural mechanisms that regulate normal cardiovascular ...
... Federation of American Societies for Experimental Biology (FASEB) ... Research Conference (SRC): Matricellular Proteins in Development, Health, ... surrounding extracellular matrix (ECM) are the basis for ... organization in all metazoan organisms. Structural ECM components ...
... Bethesda, MD The Federation of American Societies ... registration for the Science Research Conference (SRC): Hematologic ... Malignancies is an important and unique scientific conference ... and myeloma is presented in detail in the ...
Cached Biology News:FASEB SRC announces conference: Matricellular Proteins in Development, Health, and Disease 2
(Date:7/28/2015)... , July 29, 2015 A ... acquiring, rapidly developing and commercialising innovative medicines ...   Highly experienced management team; blue chip ...   Mereo BioPharma Group Ltd ("Mereo"), a ... $119m ( c. £76.5m), gross, from blue chip institutional ...
(Date:7/28/2015)... 28, 2015 Seahorse Bioscience, the industry ... the provider of XF Technology which is increasingly ... areas. As the links between mitochondrial function and ... is escalating rapidly.   Recently, 12 ... Publishing Group (NPG) featuring XF Technology, including Nature, ...
(Date:7/28/2015)... Deerfield Management Company, L.P. today announced the ... will invest in groundbreaking advancements in science that may ... orphan diseases. The venture capital fund will also back ... and improve the way healthcare is delivered to patients. ... venture funds in the sector, will donate all profits ...
(Date:7/28/2015)... PRUSSIA, Pa. , July 28, 2015 ... Food and Drug Administration has accepted for review the ... recombinant factor VIII single-chain (rVIII-SingleChain) for the treatment of ... all primary endpoints. Hemophilia A ... or defective factor VIII; nearly all affected patients are ...
Breaking Biology Technology:Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 2Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 3Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 4Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 5Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 6Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 7Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 8Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 9Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 10Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 11XF Technology Used to Demonstrate Feasibility of Stem Cell Regenerative Technique 2XF Technology Used to Demonstrate Feasibility of Stem Cell Regenerative Technique 3Deerfield Launches $550 Million Healthcare Venture-Capital Fund 2Deerfield Launches $550 Million Healthcare Venture-Capital Fund 3U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 3
... to design computer chips and electronic circuitry for extreme ... electrical engineers at Vanderbilt University has developed all the ... thin films of nanodiamond. They have created diamond versions ... a key element in computers., "Diamond-based devices have the ...
... Mass., Aug. 4, 2011 Interleukin Genetics, Inc. ... call and Webcast on Friday, August 12 at 9:30 a.m. ... To access the live call, dial 877-324-1976 (domestic) or 631-291-4550 ... will be available on the Investors section of Interleukin Genetics, ...
... N.J., Aug. 4, 2011 Palatin Technologies, Inc. (NYSE ... of a Phase 1 clinical trial of AZD2820, a ... a single-agent therapy for the treatment of obesity. AZD2820 ... collaborative research program with Palatin Technologies. Obesity ...
Cached Biology Technology:Designing diamond circuits for extreme environments 2Designing diamond circuits for extreme environments 3Interleukin Genetics, Inc. Announces Conference Call to Discuss Second Quarter 2011 Results 2Palatin Announces Commencement of a Phase 1 Trial for Obesity Compound in Collaboration with AstraZeneca 2Palatin Announces Commencement of a Phase 1 Trial for Obesity Compound in Collaboration with AstraZeneca 3
Quartz-Halogen, 100 W, High Intensity...
... System with Gateway™ Technology is designed ... the polyhedrin promoter. The expression cassette ... (bacmid DNA) by site-specific transposition (Tn7) ... recombinant bacmid DNA is then used ...
...
... Immunogen: Synthetic peptide derived from ... and bovine Math-2. Specificity: Specific ... Human Rat (positive controls: human U251 ... lysates and rat brain homogenates)Storage: Store ...
Biology Products: